Almost 900 cases of the virus have been recorded in 2024 so far, compared with 368 cases recorded 2023, according to the UK Health Security Agency (UKHSA), meaning England has seen more cases of the disease in the first four months of this year, than in the whole of last year.
In a notice on its website, the European Medicines Agency also announced the withdrawal, which means that Vaxzevria is no longer authorized to be marketed or sold in European Union countries.
Amidst the anticipated increase in vaccine-preventable diseases as the global population ages, a first-of-its-kind study has underscored the dual benefits of adult immunization programs.
A new study coming out of York University's Centre for Disease Modelling in the Faculty of Science shows that immunity after a COVID-19 booster lasts much longer than the primary series alone. These findings are among other—sometimes "unintuitive"—revelations of how factors like age, sex and comorbidities do and don't affect immune response.
The work is published in the journal Scientific Reports.
